Tsumura & Co. (JP:4540)
:4540
Want to see JP:4540 full AI Analyst Report?
4540 Stock Chart & Stats
¥3599.00
¥9.00(0.19%)
At close: 4:00 PM EST
¥3599.00
¥9.00(0.19%)
Day’s Range― - ―
52-Week Range¥3,306.00 - ¥4,403.00
Previous CloseN/A
Volume145.30K
Average Volume (3M)448.06K
Market Cap
¥285.45B
Enterprise Value¥332.05B
Total Cash (Recent Filing)¥84.08B
Total Debt (Recent Filing)¥135.16B
Price to Earnings (P/E)10.0
Beta0.51
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.3%
Share Statistics
EPS (TTM)376.59
Shares Outstanding76,758,360
10 Day Avg. Volume373,220
30 Day Avg. Volume448,060
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)0.87
Price to Sales (P/S)1.45
P/FCF Ratio-34.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)356.89
Revenue Forecast (FY)¥213.49B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent multi-year revenue expansion, including a large 2026 increase, signals durable demand and expanding market penetration for Kampo products. Sustained top-line growth supports scale advantages, funds R&D and capacity, and provides leeway to absorb pricing or reimbursement pressure.
Stable Reimbursed Prescription RevenueRevenue tied to Japan's NHI reimbursement creates predictable, recurring cash flows linked to healthcare utilization rather than retail cycles. This structural reimbursement framework reduces demand volatility and supports medium-term revenue visibility and planning for product supply and investments.
Vertical Manufacturing & Raw-Material ControlOwning manufacturing and botanical quality control lowers supply-chain disruption risk and enforces consistent product standards. Vertical integration supports regulatory compliance, differentiation in traditional medicines, and potential cost control, forming a durable operational competitive advantage.
Bears Say
Negative Free Cash FlowFCF turning negative in 2026 shows weaker cash conversion and possible elevated investment or working-capital needs. Persistent negative FCF would constrain self-funded R&D, capital spending and dividend flexibility, forcing reliance on external financing over the medium term.
Rising Debt BurdenA material rise in debt increases interest and refinancing risk and reduces strategic optionality. With leverage elevated, the company has less flexibility to fund initiatives or absorb shocks if operating cash flow remains volatile, raising medium-term financial vulnerability.
Margin Compression & Earnings DropOperating and net margin erosion alongside falling net income despite revenue growth suggests cost pressure or adverse mix. If structural, this undermines return on sales and limits the benefit of revenue gains for reinvestment, dividends and long-term profitability.
Tsumura & Co News
4540 FAQ
What was Tsumura & Co.’s price range in the past 12 months?
Tsumura & Co. lowest stock price was ¥3306.00 and its highest was ¥4403.00 in the past 12 months.
What is Tsumura & Co.’s market cap?
Tsumura & Co.’s market cap is ¥285.45B.
When is Tsumura & Co.’s upcoming earnings report date?
Tsumura & Co.’s upcoming earnings report date is Aug 11, 2026 which is in 87 days.
How were Tsumura & Co.’s earnings last quarter?
Tsumura & Co. released its earnings results on Nov 06, 2018. The company reported ¥66.265 earnings per share for the quarter, beating the consensus estimate of N/A by ¥66.265.
Is Tsumura & Co. overvalued?
According to Wall Street analysts Tsumura & Co.’s price is currently Overvalued.
Does Tsumura & Co. pay dividends?
Tsumura & Co. pays a Semiannually dividend of ¥76 which represents an annual dividend yield of 3.3%. See more information on Tsumura & Co. dividends here
What is Tsumura & Co.’s EPS estimate?
Tsumura & Co.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsumura & Co. have?
Tsumura & Co. has 76,758,360 shares outstanding.
What happened to Tsumura & Co.’s price movement after its last earnings report?
Tsumura & Co. reported an EPS of ¥66.265 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.962%.
Which hedge fund is a major shareholder of Tsumura & Co.?
Currently, no hedge funds are holding shares in JP:4540
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsumura & Co.
Tsumura & Co. (4540) is a leading Japanese pharmaceutical company specializing in traditional herbal medicine, also known as Kampo medicine. Established in 1893, the company develops, manufactures, and sells a wide range of Kampo products, which are derived from natural herbal ingredients. Tsumura operates primarily in the healthcare sector, focusing on providing effective and safe therapeutic solutions that align with Japan's rich history of herbal medicine. In addition to Kampo formulations, the company is involved in research and development of new pharmaceuticals and operates in the field of health foods.
Technical Analysis
Hisamitsu Pharmaceutical Co
―
Kaken Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Pharma Foods International Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---